Prevention of migraine in children and adolescents: results of an open-label study with special extract of Petasites hybridus root
Views: 22DOI:
https://doi.org/10.48208/HeadacheMed.2025.11Keywords:
Preventive migraine treatment, Child migraine, Adolescent migraine, Petasites hybridusAbstract
Introduction
Migraine is a genetic disease that has a major impact on life. Its prevalence is estimated to be 7.7% up to the age of 20. Preventive treatment of migraine in childhood and adolescence remains a challenge, due to the few studies conducted for this population and the presence of side effects in the use of the medications used.
Method
In this article, we evaluated the prospective open study conducted by Pothmann and Danesch using Petasites hybridus extract as a preventive treatment for migraine in children (6-9 years) and adolescents (10-17 years).
Results
This open study showed that at the end of the 4 months of treatment with Petasites hydbridus the reduction in migraine attacks in the total sample was 63.2%, 67% for children aged 6 to 9 years and 61.9% for adolescents aged 10 to 17 years. The overall response rate was 77.2%, with 85.7% for the 6- to 9-year-old group and 74.1% for the 10- to 17-year-old group. There was also a reduction in the mean duration of attacks in 62.7% of patients, from approximately 10 hours to 7 hours. No significant side effects were observed.
Conclusion
Petasites hybridus proved to be a safe and effective option for the preventive treatment of migraine in children and adolescents.
Downloads
References
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1–211. Doi:10.1177/0333102417738202. DOI: https://doi.org/10.1177/0333102417738202
Grangeon L, Lange KS, Waliszewska-Prosół M, Onan D, Marschollek K, Wiels W, et al. Genetics of migraine: where are we now? J Headache Pain 2023;24:12. Doi:10.1186/s10194-023-01547-8. DOI: https://doi.org/10.1186/s10194-023-01547-8
Messina R, Cetta I, Colombo B, Filippi M. Tracking the evolution of non-headache symptoms through the migraine attack. J Headache Pain 2022;23:149. Doi:10.1186/s10194-022-01525-6. DOI: https://doi.org/10.1186/s10194-022-01525-6
Abu‐Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population‐based studies. Dev Med Child Neurol 2010;52:1088–97. Doi:10.1111/j.1469-8749.2010.03793.x. DOI: https://doi.org/10.1111/j.1469-8749.2010.03793.x
Ozge A, Sasmaz T, Cakmak SE, Kaleagasi H, Siva A. Epidemiological-based childhood headache natural history study: After an interval of six years. Cephalalgia 2010;30:703–12. Doi:10.1177/0333102409351797. DOI: https://doi.org/10.1177/0333102409351797
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. New England Journal of Medicine 2017;376:115–24. Doi:10.1056/NEJMoa1610384. DOI: https://doi.org/10.1056/NEJMoa1610384
Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology 2019;93:500–9. Doi:10.1212/WNL.0000000000008105. DOI: https://doi.org/10.1212/WNL.0000000000008105
Ziolo G, Samochewiec L. Study on clinical Properties and mechanism of action of Petasites in bronchial asthma and chronic obstructive bronchitis. Pharm Acta Helv 1998;72:378–80.
Thomet OAR, Wiesmann UN, Schapowal A, Bizer C, Simon H-U. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. Biochem Pharmacol 2001;61:1041–7. Doi:10.1016/S0006-2952(01)00552-4. DOI: https://doi.org/10.1016/S0006-2952(01)00552-4
Rajapakse T, Davenport WJ. Phytomedicines in the Treatment of Migraine. CNS Drugs 2019;33:399–415. Doi:10.1007/s40263-018-0597-2. DOI: https://doi.org/10.1007/s40263-018-0597-2
Benemei S, Fusi C, Trevisan G, Geppetti P. TheTRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014;171:2552–67. Doi:10.1111/bph.12512. DOI: https://doi.org/10.1111/bph.12512
Fiebich BL, Grozdeva M, Hess S, Hüll M, Danesch U, Bodensieck A, et al. Petasites hybridus Extracts in vitro Inhibit COX-2 and PGE 2 Release by Direct Interaction with the Enzyme and by Preventing p42/44 MAP Kinase Activation in Rat Primary Microglial Cells. Planta Med 2005;71:12–9. Doi:10.1055/s-2005-837744. DOI: https://doi.org/10.1055/s-2005-837744
Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240–4. Doi:10.1212/01.WNL.0000147290.68260.11. DOI: https://doi.org/10.1212/01.WNL.0000147290.68260.11
Diener HC, Rahlfs VW, Danesch U. The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria. Eur Neurol 2004;51:89–97. Doi:10.1159/000076535. DOI: https://doi.org/10.1159/000076535
Pothmann R, Danesch U. Migraine Prevention in Children and Adolescents: Results of an Open Study With a Special Butterbur Root Extract. Headache: The Journal of Head and Face Pain 2005;45:196–203. Doi:10.1111/j.1526-4610.2005.05044.x. DOI: https://doi.org/10.1111/j.1526-4610.2005.05044.x
Sorge F, Marano E. Flunarizine v. Placebo in Childhood Migraine. A Double-Blind Study. Cephalalgia 1985;5:145–8. Doi:10.1177/03331024850050S227. DOI: https://doi.org/10.1177/03331024850050S227
Orr SL. Headache in Children and Adolescents. CONTINUUM: Lifelong Learning in Neurology 2024;30:438–72. Doi:10.1212/CON.0000000000001414. DOI: https://doi.org/10.1212/CON.0000000000001414
Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther 2018;35:1763–74. Doi:10.1007/s12325-018-0805-y. DOI: https://doi.org/10.1007/s12325-018-0805-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Alexandre Kaup (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
